(Q33420037)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25629741%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

title

Ruxolitinib versus standard therapy for the treatment of polycythemia vera (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25629741%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

1 reference

Jean-Jacques Kiladjian

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25629741%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Tamás Masszi

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25629741%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Francesco Passamonti

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25629741%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Pierre Zachee

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25629741%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Srdan Verstovsek

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25629741%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

8

Fabrizio Pane

1 reference

28 February 2020

Alessandro M Vannucchi

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25629741%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Martin Griesshammer

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25629741%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Simon Durrant

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25629741%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Claire N Harrison

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25629741%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Ruben Mesa

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25629741%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Shui He

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25629741%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Mark M Jones

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25629741%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

William Garrett

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25629741%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Jingjin Li

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25629741%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Ulrich Pirron

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25629741%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Dany Habr

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25629741%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

language of work or name

English

0 references

publication date

1 January 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25629741%20AND%20SRC:MED&resulttype=core&format=json

The New England Journal of Medicine

28 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25629741%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

volume

372

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25629741%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25629741%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

page(s)

426-435

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25629741%20AND%20SRC:MED&resulttype=core&format=json

Iron and mechanisms of emotional behavior

28 February 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4358820

Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patients

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4358820

Therapeutic options for patients with polycythemia vera and essential thrombocythemia refractory/resistant to hydroxyurea

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4358820

A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4358820

Emerging drugs for polycythemia vera

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4358820

Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4358820

Patients with polycythemia vera have worst impairment of quality of life among patients with newly diagnosed myeloproliferative neoplasms

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4358820

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4358820

The renaissance of interferon therapy for the treatment of myeloid malignancies

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4358820

Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4358820

Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4358820

Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4358820

Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: is leukocytosis a causative factor?

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4358820

Interferon-alpha therapy in bcr-abl-negative myeloproliferative neoplasms.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4358820

Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4358820

Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4358820

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4358820

Efficacy and safety of low-dose aspirin in polycythemia vera

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4358820

Polycythemia vera: myths, mechanisms, and management

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4358820

Long term molecular responses in a cohort of Danish patients with essential thrombocythemia, polycythemia vera and myelofibrosis treated with recombinant interferon alpha

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4358820

Treatment target in polycythemia vera

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4358820

Cardiovascular events and intensity of treatment in polycythemia vera

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4358820

Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4358820

A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4358820

High prevalence of restless legs syndrome among patients with polycytemia vera treated with venesectio.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4358820

Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4358820

Polycythemia vera and essential thrombocythemia: 2013 update on diagnosis, risk-stratification, and management

31 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25629741

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25629741

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25629741

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1056/NEJMOA1409002

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25629741%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25629741%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

1 reference